transient hypotension without compensatory tachycardia. Herein we report the effort beyond ACHN-975 to discover LpxC inhibitors optimized for enzyme potency, antibacterial activity, pharmacokinetics, and cardiovascular safety. Based on its overall profile, compound 26 (LPXC-516, (S)-N-(2-(hydroxyamino)-1-(3-methoxy-1,1-dioxidothietan-3-yl)-2-oxoethyl)-4-(6-hydroxyhexa-1,3-diyn-1-yl)benzamide) was chosen
UDP-3-O-(R-3-羟基肉豆蔻酰基)-N-乙酰
氨基
葡糖脱乙酰基酶(LpxC)是Zn2 +脱乙酰基酶,对于大多数致病性革兰氏阴性细菌的生存至关重要。ACHN-975(N-((S)-3-
氨基-1-(羟基
氨基)-3-甲基-1-氧丁丁-2-基)-4-((((1R,2R)-2-(羟甲基)环丙基)buta-1,3-diyn-1-yl)benzamide)是第一种通过人体临床测试的LpxC
抑制剂,被发现具有短暂低血压而无代偿性心动过速的剂量限制的心血管毒性。在本文中,我们报告了除ACHN-975之外的工作,以发现针对酶效力,抗菌活性,药代动力学和心血管安全性优化的LpxC
抑制剂。基于其总体概况,化合物26(LPXC-516,(S)-N-(2-(羟基
氨基)-1-(3-甲氧基-1,1-二氧
噻吩-3-基)-2-氧代乙基)-4 -(6-羟基己-1,选择3-diyn-1-yl)benzamide)进行进一步